Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma

NCT04300244 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

118

Enrollment

OTHER

Sponsor class

Conditions

Cancer
Cancer, Lung
Cancer of Lung
Mesothelioma
Mesothelioma; Lung
Mesothelioma; Pleura
Mesotheliomas Pleural

Interventions

BIOLOGICAL: UV1 vaccine + leukine
BIOLOGICAL: ipilimumab
BIOLOGICAL: nivolumab

Sponsor

Åslaug Helland

Collaborators

[object Object]
[object Object]
[object Object]